Capella 4025 Assessment 4
Capella 4025 Assessment 4
Student Name
Capella University
NURS-FPX4025 Research and Evidence-Based Decision Making
Prof. Name
Date
Presenting the PICO(T) Process Findings to Professional Peers
Urinary tract infections (UTIs) represent a prevalent and significant health issue among women, particularly those of reproductive age. The symptoms often include frequent urination, painful voiding, and lower abdominal discomfort, which can lead to recurrent medical consultations and a diminished quality of life. Studies suggest that about 41% of women in the United States will experience a UTI at some point, with nearly 10% affected annually (Bono et al., 2025). This analysis emphasizes the importance of implementing evidence-based strategies, particularly the use of prophylactic antibiotic therapy, to mitigate recurrence and decrease the burden on healthcare systems. The focus is on evaluating current antibiotic interventions that enhance outcomes in reproductive-age females.
Diagnosis: Prognosis, Risks, and Complications
Recurrent UTIs pose long-term health concerns for women, with potential complications such as kidney infections and sepsis. They are typically identified through persistent symptoms like urgency, painful urination, and systemic signs such as fever or flank pain (Bono et al., 2025). Repeated infections can result in multiple hospitalizations and increased recovery time, especially in women aged 16 to 35. Approximately half of the women with a UTI will experience a recurrence within one year. The financial impact is also substantial, with around 10 million clinic appointments and over 2 million emergency room visits occurring annually in the U.S., costing approximately \$1.6 billion (Wang & LaSala, 2021).
Comorbidities, such as diabetes, chronic kidney disease (CKD), and neurological conditions, heighten the risk for recurrent UTIs, particularly among elderly women. Research using the FRAIL scale found a statistically significant correlation between increased frailty and UTI risk. Individuals with one, two, or more frailty indicators had 19%, 24%, and 43% increased hazards, respectively (Chao et al., 2021). Additional risk factors include hormonal changes post-menopause, urinary retention, and incontinence. The frequency of UTI occurrence rises with age, from 4.5% among individuals aged 16–50 to 22% in those over 70. Women with type 2 diabetes are particularly vulnerable due to impaired immune responses and bladder dysfunction. The forecasted incidence of T2D stands at 6,058 per 10,000 individuals, underscoring the clinical relevance of comorbidity in UTI management (Bodke et al., 2023).
Mental health conditions, reduced healthcare access, and cognitive decline further exacerbate the risks. Left untreated, UTIs can escalate to severe outcomes such as pyelonephritis and multidrug-resistant infections. For example, a patient may begin with minor discomfort but develop renal complications in the absence of appropriate intervention. Early recognition, prophylactic therapies, and patient education are critical components in curbing the progression and improving clinical outcomes (Alghoraibi et al., 2023).
Formulating the PICO(T) Research Question
The clinical query developed to guide research into recurrent UTIs in adult women is: In adult women with recurrent UTIs (P), how does the use of daily prophylactic antibiotics (I), compared to no prophylactic treatment or standard care (C), influence the recurrence rate and overall patient outcomes (O) over 12 months (T)?
This question adheres to the PICO(T) structure:
| PICO(T) Component | Description |
|---|---|
| Population (P) | Adult women experiencing recurrent UTIs |
| Intervention (I) | Daily administration of prophylactic antibiotics |
| Comparison (C) | Standard care or no use of prophylactic antibiotics |
| Outcome (O) | Reduction in recurrence and enhancement of health outcomes |
| Timeframe (T) | Evaluation over a 12-month period |
This structured question allows researchers to isolate and examine the impact of preventive antibiotic therapy. Women with repeated infections often suffer from long-term health complications and reduced life quality. Daily antibiotic use offers a proactive solution as opposed to reactive treatment. Comparison with standard care highlights the necessity of preventive strategies. Expected outcomes include fewer UTI episodes, improved quality of life, and decreased hospital admissions. A year-long observation period provides ample time to assess the sustained benefits of antibiotic interventions (Luchristt et al., 2024).
Summary of Peer-Reviewed Evidence
The literature review employed systematic searches through academic databases such as PubMed, CINAHL, Cochrane Library, and Google Scholar, using the CRAAP test (Currency, Relevance, Authority, Accuracy, Purpose) to ensure source reliability (Kalidas, 2021). Four major studies provided empirical data supporting the use of prophylactic antibiotics for managing UTIs.
| Study/Source | Findings | Credibility & Relevance |
|---|---|---|
| Luchristt et al. (2024) | A one-month antibiotic regimen was more effective than three-month low-dose plans in preventing recurrences. | Published in Urology, a peer-reviewed journal. |
| Alghoraibi et al. (2023) | Prophylaxis with Nitrofurantoin and Bactrim reduced recurrence and emergency visits (P < 0.001). | Published in Epidemiology and Global Health. |
| American Urological Association (2025) | Advocates prophylactic antibiotics for women with frequent UTIs. | Official clinical guidelines; widely trusted. |
| Liu et al. (2020) | Found a 53% reduction in UTI risk after catheter removal when antibiotics were administered. | Published in American Journal of Infection Control. |
These findings underscore the value of prophylactic treatments in reducing symptom recurrence and hospitalizations, especially for high-risk patients.
Evidence-Based Response to the PICO(T) Question
The compiled evidence affirms that preventive antibiotic regimens are more effective than non-prophylactic approaches in minimizing recurrence of UTIs in adult women. Such therapies result in fewer medical appointments and emergency interventions, ultimately leading to better health and lower healthcare expenses (Luchristt et al., 2024). According to Liu et al. (2020), even post-catheter removal patients benefit significantly from such protocols. These interventions assume that patients will adhere to medication schedules and that providers are available to adjust regimens based on clinical response. Socioeconomic, mental health, and access-related factors must also be considered to ensure successful implementation. Future studies should personalize treatment models for enhanced efficacy across diverse patient groups.
Evidence-Based Clinical Implementation Steps
A strategic, evidence-driven care plan is necessary for managing recurrent UTIs among women. It involves:
- Initial Evaluation: Clinicians should perform detailed assessments to understand infection frequency and risk profile.
- Targeted Therapy: Patients meeting risk criteria should receive tailored low-dose antibiotic regimens to prevent recurrence (Alghoraibi et al., 2023).
- Patient Education: Providing guidance on symptom tracking, fluid intake, and medication adherence empowers patients and improves compliance (AUA, 2025).
These steps collectively aim to reduce infections, enhance recovery, and minimize reliance on emergency medical services.
Conclusion
This analysis emphasizes the significance of implementing evidence-based preventive measures to manage recurrent UTIs in women. Prophylactic antibiotic therapy, when applied appropriately, demonstrates the ability to lower infection rates, improve patient well-being, and decrease healthcare utilization. Integrating these strategies into clinical practice enhances patient quality of life while promoting efficient healthcare delivery.
References
Alghoraibi, A., Asidan, A., Aljawaied, A., Almukhayzim, N., Alsaydan, R., Alamer, S., Baharoon, S., Masuadi, E., Shukairi, F., Layqah, L., & Baharoon, D. (2023). Recurrent urinary tract infection in adult patients, risk factors, and efficacy of low dose prophylactic antibiotics therapy. Journal of Epidemiology and Global Health, 13(2), 200–211. https://doi.org/10.1007/s44197-023-00105-4
American Urological Association. (2025). Recurrent Uncomplicated Urinary Tract Infections in Women: AUA Guidelines. https://www.auanet.org
Bodke, R., Shah, S., & Luthra, A. (2023). Type 2 diabetes and susceptibility to urinary tract infections: A clinical overview. Journal of Clinical Diabetology, 14(3), 187–195.
Bono, M. J., Carter, M., & Parnell, M. (2025). Understanding recurrent urinary tract infections in young women: Prevalence and implications. Urology Clinics of North America, 52(1), 45–58.
Chao, C. T., Hsu, Y. H., & Chen, H. Y. (2021). Frailty and risk of urinary tract infections among older adults with chronic illnesses. Geriatrics & Gerontology International, 21(4), 346–353.
Capella 4025 Assessment 4
Kalidas, S. (2021). Evaluating information: The CRAAP test revisited. Journal of Academic Librarianship, 47(1), 102293.
Liu, C., Wang, Q., & Zhao, Y. (2020). Antibiotic prophylaxis for urinary tract infection after catheter removal: A systematic review. American Journal of Infection Control, 48(2), 154–160. https://doi.org/10.1016/j.ajic.2019.08.031
Luchristt, M., Rios, E., & Anderson, H. (2024). Comparative effectiveness of prophylactic antibiotic regimens for recurrent UTIs in adult females. Urology, 168, 89–97. https://doi.org/10.1016/j.urology.2024.01.010
Wang, L., & LaSala, K. (2021). The economic burden of urinary tract infections in the United States. Health Economics Review, 11(1), 23. https://doi.org/10.1186/s13561-021-00312-2